Products with Anticancer bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN3513 | RA-V |
| 1. RA-V is an potential anti-angiogenic agent, exhibits anti-angiogenic activities in HUVEC and HMEC-1 cell lines with changes in function of these endothelial cells. 2. RA-V has anti-cancer activity, is a potential anti-metastatic agent in breast cancer, and likely acts via PI3K/AKT and NF-κB signaling pathways in both ER-positive and ER-negative breast cancer cells. | |
| BCN3514 | RA-XI |
| 1. RA-XI shows potent antitumor activity against P-388. | |
| BCN3522 | Curcumenol |
| Curcumenol possesses a variety of health and medicinal values which includes neuroprotection, anti-inflammatory, anti-tumor and hepatoprotective activities. It inhibits NF-κB activation by suppressing the nuclear translocation of the NF-κB p65 subunit and blocking IκBα phosphorylation and degradation. | |
| BCN3536 | 3-Hydroxy-1,5-diphenyl-1-pentanone |
| 1. (+)-3-Hydroxy-1,5-diphenyl-1-pentanone exhibits both immunomodulatory and anti-tumor activity. | |
| BCN3551 | Ginsenoside Rg5 |
| 1. Ginsenoside Rg5 could be a beneficial agent for the treatment of Alzheimer's disease. 2. Ginsenoside Rg5 suppresses LPS-induced nitric oxide (NO) production and proinflammatory TNF-α secretion. 3. Ginsenoside Rg5 can ameliorate lung inflammation possibly by inhibiting the binding of LPS to toll-like receptor (TLR)-4 on macrophages. 4. Ginsenoside Rg5 plays a novel role as an IGF-1R agonist, promoting therapeutic angiogenesis and improving hypertension without adverse effects in the vasculature. 5. Ginsenoside Rg5 blocks cell cycle of SK-HEP-1 cells at the Gl/S transition phase by down-regulating cyclin E-dependent kinase activity and that the down-regulation of cyclin E-dependent kinase activity is caused mainly by induced CDK2 inhibitor, p21Cip/WAF1 and decreased levels of cyclin E. | |
